Lenvatinib Biogaran (Lenvatinib)

Lenvatinib inhibits multiple receptor tyrosine kinases such as VEGFR 1‑3, FGFR 1‑4, PDGFRα, RET and KIT. Blocking these receptors reduces angiogenesis, limits tumour cell proliferation and disrupts the supportive tumour micro‑environment, thereby slowing disease progression.

The dose of Lenvatinib is individualized by the treating physician based on the specific cancer type, patient characteristics and any concomitant therapies. Only a qualified prescriber can determine the appropriate strength, schedule and duration of treatment.

Safety data for Lenvatinib during pregnancy or lactation are limited, and the drug may cause fetal harm. It is generally advised to avoid use in pregnant or nursing women unless the potential benefit justifies the potential risk, and to discuss alternatives with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lenvatinib Biogaran. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenvatinib is a multi‑targeted tyrosine kinase inhibitor, offering oral administration and a broad receptor profile. Compared with agents such as sorafenib, it provides additional inhibition of FGFR and RET, which can translate into different efficacy and safety profiles. Choice of therapy depends on tumour type, prior treatments and individual patient factors.

Lenvatinib should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Lenvatinib is taken orally, usually once daily, with a glass of water. It can be swallowed with or without food, but patients should follow the specific instructions provided by their prescriber and avoid crushing or chewing the tablets.

The most serious adverse events include severe hypertension, hepatic failure, major bleeding, and the development of fistulas. Patients should be monitored regularly for blood‑pressure spikes, liver‑function abnormalities, signs of bleeding and any unusual wound healing problems.

Lenvatinib is contraindicated in patients with known hypersensitivity to the drug or any of its excipients, and it should be avoided in individuals with uncontrolled cardiovascular disease, severe hepatic impairment, or active bleeding disorders unless the prescriber determines that benefits outweigh the risks.